Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Want to see IMDX full AI Analyst Report?
Top Page
Insight Molecular Diagnostics
(NASDAQ:IMDX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$5.50
▲(73.50% Upside)
Action:Reiterated
Date:06/18/26
The score is primarily held down by weak financial performance, including sharply lower TTM revenue, persistent large losses, heavy cash burn, and negative equity. Technicals are mixed/neutral, offering limited support. The latest earnings call adds some offset through concrete regulatory and commercialization progress and specific margin/cost targets, but near-term revenue guidance is very low and cash burn remains high, keeping overall risk elevated.
Positive Factors
FDA submission and active engagement
An FDA submission with active, productive engagement materially de-risks U.S. market access. Continued review interaction and the expectation of first U.S. orders later this year create a clear path from development to revenue, supporting commercialization planning and partner/customer discussions over the coming months.
Negative Factors
Severe cash burn and negative free cash flow
Persistent multi‑million-dollar operating and free cash flow deficits mean the business cannot self-fund growth and relies on external capital. That dynamic compresses strategic flexibility, raises dilution and refinancing risk, and can constrain commercialization and instrument placement timelines absent additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA submission and active engagement
An FDA submission with active, productive engagement materially de-risks U.S. market access. Continued review interaction and the expectation of first U.S. orders later this year create a clear path from development to revenue, supporting commercialization planning and partner/customer discussions over the coming months.
Read all positive factors
Insight Molecular Diagnostics (IMDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$175.66M
Dividend YieldN/A
Average Volume (3M)42.75K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth-49.28%
EPS Growth57.96%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue60.37
Enterprise Value/Gross Profit310.05
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$10.50Price Target Upside231.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.59M
Insight Molecular Diagnostics Business Overview & Revenue Model
Company Description
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States...
Insight Molecular Diagnostics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.Positive Updates
FDA Submission and Strong Engagement
Submitted GraftAssureDx to the FDA in late March and reported high, productive engagement during the review process; company expects continued interaction and anticipates first U.S. orders later this year.
Negative Updates
Near-Term Revenue Is Low
Q2 2026 revenue projection of approximately $0.25 million (primarily laboratory services and minimal GraftAssureIQ sales), indicating immaterial near-term commercial revenue.
Read all updates
Q1-2026 Updates
Positive
Negative
FDA Submission and Strong Engagement
Submitted GraftAssureDx to the FDA in late March and reported high, productive engagement during the review process; company expects continued interaction and anticipates first U.S. orders later this year.
Read all positive updates
Company Guidance
Management gave specific near-term financial and commercial guidance: Q2 2026 revenue is projected at about $0.25M (mostly lab services, very low GraftAssureIQ sales) and Q2 cash burn is expected above $9M (the year’s high watermark), with cash burn forecast to decline in H2 toward historical levels of roughly $6M/quarter as R&D spend and one-time FDA program expenses taper; they reiterated Medicare reimbursement of $2,753 per GraftAssureCore result, a ~$2B total addressable market, an expected ASP “in the hundreds,” COGS slightly under $100/result, a 10% revenue share to former Chronix shareholders, and a long‑term gross‑margin target of ~70%+, plus operational and regulatory milestones including GraftAssureDx submitted to the FDA in late March (first U.S. orders expected later this year), 34 U.S. centers engaged in the GALACTIC registry (up from 28 six weeks ago toward a 50‑center goal) with first‑patient revenue expected this year, TUV SUD ISO 13485 certification in February, planned UK IVDD/European IVDR filings (EU review guidance ~6–12 months), and early RUO orders in Switzerland and Southeast Asia.Insight Molecular Diagnostics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.95M | 4.05M | 1.88M | 1.50M | 958.00K | 2.20M |
| Gross Profit | 379.50K | 190.00K | 740.00K | 413.00K | -18.00K | 1.42M |
| EBITDA | -45.40M | -47.92M | -59.02M | -23.12M | -13.31M | -48.46M |
| Net Income | -47.84M | -50.22M | -60.66M | -27.78M | -72.90M | -64.10M |
Balance Sheet | ||||||
| Total Assets | 40.43M | 25.76M | 35.08M | 74.89M | 100.09M | 159.56M |
| Cash, Cash Equivalents and Short-Term Investments | 28.20M | 11.58M | 8.64M | 9.43M | 20.43M | 33.85M |
| Total Debt | 3.07M | 3.50M | 3.66M | 2.87M | 3.54M | 5.68M |
| Total Liabilities | 51.12M | 57.22M | 47.35M | 54.42M | 60.50M | 94.35M |
| Stockholders Equity | -10.69M | -31.46M | -12.27M | 20.47M | 39.59M | 65.22M |
Cash Flow | ||||||
| Free Cash Flow | -27.46M | -25.37M | -21.23M | -23.61M | -49.91M | -38.19M |
| Operating Cash Flow | -23.96M | -22.18M | -20.71M | -23.32M | -45.57M | -35.94M |
| Investing Cash Flow | -3.49M | -3.19M | -512.00K | -932.00K | -4.34M | -13.96M |
| Financing Cash Flow | 24.21M | 28.07M | 20.43M | 12.19M | 35.81M | 78.36M |
Insight Molecular Diagnostics Technical Analysis
Neutral
3.17
Price Trends
5.02
Positive
5.10
Positive
5.22
Positive
Market Momentum
0.04
Positive
48.24
Neutral
22.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMDX, the sentiment is Neutral. The current price of 3.17 is below the 20-day moving average (MA) of 5.88, below the 50-day MA of 5.02, and below the 200-day MA of 5.22, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 22.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMDX.
Insight Molecular Diagnostics Risk Analysis
Insight Molecular Diagnostics disclosed 53 risk factors in its most recent earnings report. Insight Molecular Diagnostics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Insight Molecular Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $46.86M | 0.91 | -560.64% | ― | -32.64% | 56.66% | |
50 Neutral | $175.66M | -3.93 | 380.80% | ― | -49.28% | 57.96% | |
47 Neutral | $262.52M | -3.72 | -147.80% | ― | 1.97% | -25.03% | |
45 Neutral | $269.94M | -0.74 | 309.79% | ― | -35.61% | -68.92% | |
42 Neutral | $20.05M | -0.46 | -84.91% | ― | ― | -40.23% |
* Healthcare Sector Average
IMDX
Insight Molecular Diagnostics
5.44
1.78
48.63%
ATOS
Atossa Therapeutics
2.01
-9.99
-83.24%
MGNX
MacroGenics
4.13
2.81
212.88%
ELUT
Elutia
1.06
-0.68
-39.08%
SRZN
Surrozen
23.25
14.23
157.76%
TELO
Telomir Pharmaceuticals, Inc.
1.42
-0.27
-15.98%
Insight Molecular Diagnostics Corporate Events
Executive/Board ChangesShareholder Meetings
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
Positive
Jun 17, 2026
Insight Molecular Diagnostics held its annual shareholder meeting on June 11, 2026, via live webcast, with 74.19% of voting power represented, and shareholders elected four directors—Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Sil...
Regulatory Filings and Compliance
Insight Molecular Corrects Bylaws Disclosure in Annual Report
Neutral
Apr 30, 2026
On March 26, 2026, Insight Molecular Diagnostics Inc. disclosed that its Annual Report on Form 10-K for the year ended December 31, 2025, mistakenly incorporated an incorrect version of its Third Amended and Restated Bylaws. The error involved the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.